

Cardiovascular Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that Committee members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by Committee members, NQF is requiring the following recusals be made during the measure evaluation period.

Measures Under Review (June 30, 2020) & Committee Member Recusals

Measure Number	Measure Title	Measure Steward	Committee Member Recusals
0066	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	American Heart Association	Howard Eisen, MD Medical Director of the Cardiac Transplant, Mechanical Circulatory Support and Advanced Heart Failure Programs